Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

32.01 -0.18 (-0.56%)
Streaming Delayed Price Updated: 10:53 AM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
2 No-Brainer Dividend Stocks to Buy With $100 in October
With their high yields and strong underlying businesses, these stocks are hard to pass up. 
Via The Motley Fool
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Now could be a great time to scoop up three stocks trading way below their previous peaks. 
Via The Motley Fool
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
These dividend payers could more than double their payouts in the decade ahead. 
Via The Motley Fool
NASDAQ:RPRX: good value for what you're paying.
Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Looking Into Royalty Pharma's Recent Short Interest
Via Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals. 
Via Chartmill
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round." 
Via Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Royalty Pharma's Earnings: A Preview
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
Via Benzinga
Exposures Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
Via Investor's Business Daily
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. 
Via Benzinga
7 Dividend Stocks to Buy at a 52-Week Low
For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low. 
Via InvestorPlace
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
Via Benzinga
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio. 
Via InvestorPlace
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April. 
Via InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
Analysts are quite bullish about these beaten-down stocks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.